Clinical Trials
37 trialsALCG-01
Gazi University
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
NeoLATC
Fujian Medical University
Oncomabs
Oslo University Hospital
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
University of Pittsburgh
International Multicentric Study ARON-1
Hospital of Macerata
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Intergruppo Melanoma Italiano
Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab
Commonwealth Healthcare Corporation
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Asan Medical Center
APiTOXMM
University Hospital, Montpellier
Imaging FDG Flare in Melanoma
Abramson Cancer Center at Penn Medicine
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
Aetion, Inc.
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
Aetion, Inc.
EROS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
Universitaire Ziekenhuizen KU Leuven
Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab
University Medical Center Groningen
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
TREATMENT
Oslo University Hospital
NSCLC
Assiut University
I-STOP
University of Milano Bicocca
Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
Aetion, Inc.
PORTRAIT
Vall d'Hebron Institute of Oncology
PASIP
Royal Free Hospital NHS Foundation Trust
ST-ICI
University of Erlangen-Nürnberg Medical School
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
QUASAR
University of California, San Diego
PROBES
Nanfang Hospital, Southern Medical University
Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients
Aarhus University Hospital
Esporta
Hunan Province Tumor Hospital
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
European Lung Cancer Working Party
A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients
Sichuan University
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Peking Union Medical College Hospital
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients
Kiang Wu Hospital
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
Guangdong Association of Clinical Trials